Dermatology Times is looking back on the top stories in dermatology from the month of September.
News|Articles|October 5, 2026
Dermatology Times Monthly FDA and Pipeline Review: September 2026
Author(s)Shannon Heaning, Content Associate
New indications for superficial basal cell carcinoma and adolescent alopecia areata expanded treatment options, while psoriasis and rare disease candidates advanced through FDA review.
Advertisement
Advertisement
September brought regulatory progress across skin cancer, alopecia areata, psoriasis, and rare genetic disorders. Alongside 2 indication expansions, the month delivered Priority Review decisions, a Fast Track designation, and clinical findings that moved some development programs forward while ending another.
Related to this article
Explore the top headlines of the month, including insights on the latest clinical trials, therapeutic updates, and more.
From next-generation oral therapies and long-term disease control to precision medicine, EADV 2026 highlighted a dermatology landscape increasingly focused on deeper, durable, and individualized outcomes.
The final day of EADV 2026 explored precision medicine, molecular profiling, atopic dermatitis research, real-world evidence, and emerging approaches to individualized dermatologic care.
New EADV 2026 data highlighted real-world outcomes in adults with chronic hand eczema and improvements in itch, pain, and quality of life among adolescents treated with delgocitinib cream.
Day 3 of EADV 2026 featured long-term psoriasis data, advances in hidradenitis suppurativa, evolving approaches to atopic dermatitis, and late-breaking research.
Seven presentations will highlight phase 3 maintenance and induction findings, 3-year phase 2 data, and preclinical research evaluating obefazimod in ulcerative colitis.
Updated phase 2 results from the AMETHYST study showed continued improvements in skin disease activity through 52 weeks, with more than one-quarter of patients achieving clear or almost clear skin.
Advertisement
Advertisement